According to the Zhitong Finance and Economics APP, Innovent Bio (01801) rose nearly 3%, as of press time, the rise was 2.95%, at HKD 40.10, with a turnover of HKD 49.3419 million.

On the news front, on August 2nd, according to the National Medical Products Administration, the National Medical Products Administration has approved the Beijing Municipal Drug Administration and the Shanghai Municipal Drug Administration's application to carry out trial reforms for innovative drugs in clinical trials in Beijing and Shanghai. The pilot will be carried out in strict accordance with the requirements of the"Pilot Work Plan for the Optimization of Innovative Drug Clinical Trial Evaluation and Approval."

In addition, Innovent Bio announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has formally accepted the second new drug application (NDA) for the dual GLP-1R/GCGR agonist Mosdopipant (research and development code: IBI362), for blood glucose control in adults with type 2 diabetes (T2D).